Recent Updates
Recently added Catalysts
TECH Positive Sentiment

BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences ...

Key Takeaway: Bio-Techne Corporation announced that Will Geist, President of the Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. This presentation indicates the company's commitment to engaging with investors and highlighting its innovations in the life sciences sector. Bio-Techne has a robust portfolio of products designed for research and clinical diagnostics, generating over $1.1 billion in net sales in fiscal 2023. The event will be accessible via a live webcast for wider audience participation.
Price reaction · baseline $75.13 (2024-03-11 close) · hit after-hours · clean, no other TECH news in the window
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Bio-Techne is actively participating in a prestigious investor forum.
  • The company continues to demonstrate strong financial performance with $1.1 billion in net sales.
  • The involvement of the President of Protein Sciences Segment showcases leadership engagement.

Full Press Release Details

MINNEAPOLIS , March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced that Will Geist , President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024 , at 9:45 a.m. EDT . A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .
About Bio-Techne (NASDAQ: TECH )
Bio-Techne Corporation (NASDAQ: TECH ) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook , LinkedIn , Twitter or YouTube .
Contact: David Clair, Vice President, Investor Relations & Corporate Development
[email protected]
612-656-4416

Frequently Asked Questions

When will Bio-Techne present at the KeyBanc Investor Forum?

Bio-Techne will present on March 19, 2024, at 9:45 a.m. EDT.

How can I access the live webcast of the presentation?

The live webcast will be available on Bio-Techne's Investor Relations website.

What does Bio-Techne specialize in?

Bio-Techne specializes in innovative tools and bioactive reagents for life sciences.

What were Bio-Techne's net sales in fiscal 2023?

In fiscal 2023, Bio-Techne generated over $1.1 billion in net sales.

How many employees does Bio-Techne have worldwide?

Bio-Techne has approximately 3,100 employees globally.

Last updated: Mar 12, 2024